Pfizer Aktie
21,21
EUR
-0,25
EUR
-1,14
%
24,55
USD
+0,02
USD
+0,06
%
nachbörslich
Kursziele der Pfizer-Aktie in USD
Das durchschnittliche Kursziel beinhaltet alle Analysen eines Analysten und nicht nur die jeweils aktuellste Analyse, die im Chart dargestellt wird.
Diese Analysten bewerten die Pfizer-Aktie
| Analyst | Kursziel | Abstand Kursziel | Datum | |
|---|---|---|---|---|
| UBS AG | 25,00 USD | +1,87% | 13.06.2025 | |
| Bernstein Research | 30,00 USD | +22,25% | 04.06.2025 | |
| JP Morgan Chase & Co. | 30,00 USD | +22,25% | 03.06.2025 | |
| Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | 25,00 USD | +1,87% | 29.05.2025 | |
| Jefferies & Company Inc. | 33,00 USD | +34,47% | 21.05.2025 | |
| DZ BANK | - | - | 05.02.2025 | |
| Goldman Sachs Group Inc. | 32,00 USD | +30,40% | 05.02.2025 |
Werbung
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| Abbott Laboratories | 0 | 0 | 0 | - | - |
| Alexion Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Allergan Inc. | 0 | 0 | 0 | - | - |
| APONTIS PHARMA | 0 | 0 | 0 | - | - |
| AstraZeneca PLC | 6 | 3 | 0 | 136,60 GBP | - |
| Bayer | 2 | 7 | 0 | 26,00 EUR | -5,27% |
| Celgene Corp. | 0 | 0 | 0 | - | - |
| EVOTEC SE | 2 | 3 | 0 | 9,96 EUR | +34,23% |
| Gilead Sciences Inc. | 0 | 0 | 0 | - | - |
| GSK PLC Registered Shs | 1 | 6 | 1 | 16,30 GBP | +7,84% |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| Merck Co. | 0 | 0 | 0 | - | - |
| Merck KGaA | 7 | 1 | 0 | 165,86 EUR | +44,48% |
| MorphoSys | 0 | 0 | 0 | - | - |
| Mylan N.V. | 0 | 0 | 0 | - | - |
| Novartis AG | 3 | 5 | 1 | 99,75 CHF | +2,67% |
| Perrigo Company | 0 | 0 | 0 | - | - |
| Pfizer Inc. | 3 | 4 | 0 | 29,00 USD | +18,17% |
| Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
| Sanofi S.A. | 6 | 3 | 0 | 116,12 EUR | +34,09% |
| STADA | 0 | 0 | 0 | - | - |
| Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 0 | 0 | 0 | - | - |
| Vertex Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Warner Chilcott plc | 0 | 0 | 0 | - | - |